PTPN22 and bone destruction in RA 25

First Page		Document Content
Arthritis Rheumatologists Autoimmune diseases Rheumatology Rheumatoid arthritis Anti-citrullinated protein antibody Autoimmunity Peter K. Gregersen Rheumatoid factor Health Medicine Biology		PTPN22 and bone destruction in RA 25 Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 40,54 KB Share Document on Facebook

	ADVANCES IN RHEUMATOLOGY Affiliated with Columbia University College of Physicians and Surgeons and Weill Cornell Medical College NOVEMBER/DECEMBER 2014 The rheumatology program at NewYorkPresbyterian Hospital is compris DocID: 1fzzx - View Document
	Presentation of Navigare Patient Flow and Positioning Product Group: Biological Drugs Target Groups: Rheumatologists Dermatologists Gastroenterologists Countries: DocID: 1eAsN - View Document
	Developed in Partnership with Rheumatologists Raintree Delivers EMR and Practice Management in a Single Software Solution DocID: 1d2Up - View Document
	Important Safety Information for Rheumatologists About Risks in Patients Receiving ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administrati DocID: 1bTad - View Document
	542 CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials DocID: 1anTs - View Document